



ScienceDirect

Contents lists available at [sciencedirect.com](http://sciencedirect.com)  
Journal homepage: [www.elsevier.com/locate/jval](http://www.elsevier.com/locate/jval)

Systematic Literature Review

## Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review



Lesong Conteh, PhD,\* Kathryn Shuford, MPH, Efundem Agboraw, PhD, Mara Kont, Msc, Jan Kolaczinski, PhD, Edith Patouillard, PhD\*

### ABSTRACT

**Objectives:** To systematically review the literature on the unit cost and cost-effectiveness of malaria control.

**Methods:** Ten databases and gray literature sources were searched to identify evidence relevant to the period 2005 to 2018. Studies with primary financial or economic cost data from malaria endemic countries that took a provider, provider and household, or societal perspective were included.

**Results:** We identified 103 costing studies. The majority of studies focused on individual rather than combined interventions, notably insecticide-treated bed nets and treatment, and commonly took a provider perspective. A third of all studies took place in 3 countries. The median provider economic cost of protecting 1 person per year ranged from \$1.18 to \$5.70 with vector control and from \$0.53 to \$5.97 with chemoprevention. The median provider economic cost per case diagnosed with rapid diagnostic tests was \$6.06 and per case treated \$9.31 or \$89.93 depending on clinical severity. Other interventions did not share enough similarities to be summarized. Cost drivers were rarely reported. Cost-effectiveness of malaria control was reiterated, but care in methodological and reporting standards is required to enhance data transferability.

**Conclusions:** Important information that can support resource allocation was reviewed. Given the variability in methods and reporting, global efforts to follow existing standards are required for the evidence to be most useful outside their study context, supplemented by guidance on options for transferring existing data across settings.

**Keywords:** cost-effectiveness, disease control interventions, malaria, unit cost.

VALUE HEALTH. 2021; 24(8):1213–1222

## Introduction

No significant reduction in malaria burden has been recorded since 2015, and in some countries, the disease burden is on the rise.<sup>1</sup> In 2018, 6 countries accounted for more than half of all malaria cases (Nigeria, the Democratic Republic of the Congo, Uganda, Côte d'Ivoire, Mozambique, and Niger), and children under 5 years of age represented two thirds of the 405 000 malaria-related deaths globally.<sup>1</sup> The level of global investments in malaria is reported to be below the estimated resource needs to achieve progress targets.<sup>2–5</sup> Under tight funding constraints, evidence on the unit cost and cost-effectiveness of malaria control interventions becomes ever more important, and how resources are allocated comes under increasing scrutiny. We update previous malaria control unit cost and cost-effectiveness reviews<sup>6–10</sup> and widen the scope of evidence by adding new data and interventions with the aim to inform decision-making processes for national malaria control strategies.

## Methods

### Search Strategy and Selection Criteria

We searched peer-reviewed studies from Medline, Embase, Econlit, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, Cochrane Library, Web of Science, and the Latin American and Caribbean Health Sciences Literature and gray literature from GreyNet/OpenSIGLE, the Social Science Research Network, and the websites of the World Bank Group, the World Health Organization (WHO), the United States Agency for International Development, and Population Services International. Searches were restricted to studies published between January 1, 2005, and August 31, 2018. Before 2005, the set of malaria control interventions implemented by countries was relatively limited; some of these interventions are not recommended anymore, while others had very low coverage and have since been replaced by different commodities. Our

\*Drs Conteh and Patouillard contributed equally to this work.

project started in June 2018, and we stopped searches in September 2018. We used English search terms (see [Appendix 1](#) in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>) only but considered studies published in English, French, or Spanish. Reference lists of eligible studies were reviewed and topic experts consulted to identify additional articles for inclusion. Studies included had to contain primary cost data on 1 or more WHO-recommended malaria control interventions and take a provider, provider and household, or societal perspective. Excluded were studies that: (1) exclusively relied on mathematical modeling of cost data published by other studies; (2) took a household perspective only; (3) were found in poster presentation or conference abstract formats only; or (4) pertained to the health of short-term travelers from non-endemic to endemic countries. The study protocol was registered under Prospero, number CRD42018105625.

### Data Management and Analysis

Titles and abstracts were imported into the Covidence systematic review online management tool. Three reviewers independently screened titles and abstracts, retrieved full texts of potentially relevant studies, and assessed study eligibility for inclusion; discrepancies were resolved by a fourth reviewer. Review team members extracted the data independently using a table developed following discussions with investigators from the Global Health Costing Consortium.<sup>11</sup> Extracted data included: the characteristics of each eligible study (first author, publication year, country name, rural/urban or mixed study setting); details of the studied intervention (type, delivery strategy, and/or platform; population targeted; number of commodities distributed or area covered if applicable); the analytical methods (study perspective, including provider/household and provider or societal; financial or economic cost; unit cost output measure, cost-effectiveness health outcome measure where applicable); and the results (unit cost or cost-effectiveness estimate; breakdown of unit cost data by cost category, by resource input, and/or activity where available).

When a study provided data for several years, only data from the most recent year were extracted. If unit cost data were not explicitly reported by studies, data on total cost and number of commodities delivered or individuals covered by an intervention were used. When the cost per treatment course was not reported by a study, we estimated it using cost per dose data reported by the study and WHO treatment recommendations to allow output cost comparability across studies. Malaria treatment at outpatient departments was considered uncomplicated malaria treatment, whereas health facility admissions were assumed to be severe cases. For graphical display, percentage unit cost category data were converted to absolute terms.

Summary statistics were calculated by intervention, perspective, and unit cost output and/or cost-effectiveness health outcome measure when more than 3 data points were available. We present economic rather than financial data to better reflect resource use. All cost data were converted to constant USD 2018.<sup>12</sup> Cost data in currencies other than US dollars were first converted from the local currency to US dollars using the exchange rate at the year of costing before being inflated to 2018 USD.<sup>13</sup>

## Results

The search yielded 16 985 records. Using Covidence, 6505 duplicates were removed. A further 9621 records were excluded by title or abstract; 859 full-text articles were read and 754 were excluded, of which 180 were duplicates previously unidentified by

Covidence, and 576 studies did not meet our inclusion criteria. A total of 103 eligible studies were identified. This section summarizes key results across eligible studies before describing in more detail results by intervention type.

### Overview of Results

Eligible studies concerned vector control interventions ( $n = 32$ , 31%), chemoprevention in special risk groups ( $n = 12$ , 12%), diagnostics ( $n = 18$ , 17%), treatment ( $n = 21$ , 20%), surveillance ( $n = 9$ , 9%), and combinations of 2 or more interventions ( $n = 11$ , 11%) ([Fig. 1](#)). The number of eligible studies peaked at 14 in 2014 and 2017 (see [Appendix 2](#) in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>). The eligible studies covered a total of 39 countries, with one third of the studies concerned with the unit cost and cost-effectiveness of malaria control in 3 sub-Saharan African countries only, including Tanzania ( $n = 22$ ), Ghana ( $n = 13$ ), and Zambia ( $n = 12$ ) ([Fig. 2](#)). Fewer studies concerned other regions, including the Eastern Mediterranean region ( $n = 3$ ), the Southeast Asia region ( $n = 3$ ), the Western Pacific region ( $n = 5$ ), and the region of the Americas ( $n = 4$ ). Less than one fifth (18%) of the eligible studies took place in 1 of the 6 countries that together accounted for more than half of all malaria cases worldwide in 2018.<sup>1</sup> When interpreting the geographical distribution and intervention type of studies, however, it is important to note that among the eligible studies were both multi-country (11%) and multi-intervention (11%) studies.

From a provider perspective, the median economic cost of protecting 1 person from malaria ranged from \$1.18 to \$5.70 with vector control and from \$0.53 to \$5.97 with chemoprevention. The median provider economic cost per case diagnosed was \$6.06 with rapid diagnostic test (RDT) and \$2.53 with microscopy, while it was per case treated \$9.31 and \$89.93 for uncomplicated and severe malaria, respectively. For surveillance and combinations of interventions, the types of activities and the range of unit cost output measures used in the eligible studies did not share enough similarities to be summarized.


### Vector Control

Vector control interventions include measures against malaria-transmitting mosquitoes intended to limit mosquitoes' ability to transmit the disease. Vector control eligible studies investigated the cost of the 2 core vector control interventions, including insecticide-treated nets (ITNs) ( $n = 26$ , 81%),<sup>14-39</sup> and/or indoor residual spraying (IRS) ( $n = 3$ , 9%)<sup>23,37,40</sup> or larval source management (LSM) ( $n = 5$ , 16%),<sup>41-45</sup> a supplementary vector intervention. Seven ITN,<sup>14,19-21,29,37-39</sup> 1 IRS,<sup>37</sup> and 1 LSM<sup>43</sup> studies were also cost-effectiveness studies.

#### Insecticide-treated bed nets (ITN)

ITN are either conventionally treated nets that rely on periodic retreatment of nets by dipping into an insecticide formulation or factory-treated, pyrethroid-only, long-lasting insecticide nets (LLINs) made of netting material with insecticide incorporated within or bound around the fibers. A net needs to retain its effective biological activity for 3 years of recommended use under field conditions to qualify as an LLIN. Most ITN studies considered pyrethroid-only long-lasting insecticide nets (LLIN),<sup>15,16,18,19,22,24-29,31-36,38</sup> the most common type of ITN currently deployed, whereas others, published before 2009, examined ITN with pyrethroid insecticide retreatment.<sup>17,21,30,37-39</sup> More than half of ITN studies investigated continuous distribution, while others ( $n = 9$ , 35%) analyzed campaigns (see [Appendix 3](#) in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

Figure 1. PRISMA flow chart.



### Indoor-residual spraying (IRS)

IRS involves spraying interior surfaces of dwellings with a residual insecticide to kill or repel endophilic mosquitoes. Of the 3 eligible IRS studies, 1 concerned 2017 cost estimates of the United States President's Malaria Initiative IRS programs across 12 countries<sup>40</sup> while the other 2 analyzed initiatives from 2006<sup>23</sup> or before 2000<sup>37</sup> (see Appendix 3 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

### Larval source management (LSM)

LSM involves the management of aquatic habitats, which are potential habitats for mosquito larvae, to prevent completion of development of the immature stages. LSM studies concerned larviciding,<sup>41-45</sup> which is the regular application of biological or chemical insecticides to water bodies. All but one<sup>42</sup> were published after 2010<sup>41,43-45</sup> (see Appendix 3 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).


### Unit cost and cost-effectiveness of vector control interventions

From a provider perspective, the median economic cost per person protected per year (PPPY) with ITN was US\$1.39

(interquartile range [IQR] 0.72),<sup>25-27,34-36</sup> with IRS \$5.70 (IQR 2.0)<sup>37,39,40</sup> and with larviciding \$1.18 (IQR 0.54) (see Appendix 3 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).<sup>43-45</sup> Additional unit economic cost measures for ITN included \$1.77 (IQR 1.46) per treated net year (TNY)<sup>18,26,27,30,34-36</sup> and \$5.13 (IQR 3.76) per net distributed (Appendix 3).<sup>14,16,18,20,21,25-27,29-37,39</sup> Cost category data suggest that nets represent nearly half of the cost per ITN distributed, while once excluded, personnel is the main cost category, followed by education/communication activities (IEC) and transport (see Appendix 4 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>). IRS and larviciding studies suggested insecticide to be the largest cost category, followed for IRS by project management and spray operations (see Appendix 5 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>) and for larviciding by personnel (see Appendix 6 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

Of all the interventions, ITNs had the most cost-effectiveness data. ITN cost-effectiveness compared with no ITN was \$5.85 per episode averted (IQR 5.96)<sup>20</sup> and, on average, \$1281.97 (IQR 998.24) per death averted<sup>14,20,21,37-39</sup> and \$44.51 (IQR 35.04) per

**Figure 2.** Geographical distribution of eligible studies by intervention and study type.



DALY averted<sup>14,20,38,39</sup> from a provider perspective across several sub-Saharan African settings (Table 1). Using different insecticides in South Africa and Mozambique, IRS cost-effectiveness compared to no IRS, from the provider perspective, was \$840.44 per death averted and \$25.16 per DALY averted.<sup>37</sup> In a high-transmission setting of Tanzania, larviciding cost-effectiveness compared to no larviciding was \$2.62 per case averted, \$2412.17 per death averted, and \$46.87 per DALY averted from a societal perspective<sup>43</sup> (see Appendix 3 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

**Chemoprevention**

Chemoprevention is used for preventive treatment using antimalarial medicines and aims to prevent malarial illness by maintaining therapeutic drug levels in the blood throughout the period of greatest risk.

Eligible studies concerned seasonal chemoprevention in children (SMC) (n = 5, 42%)<sup>46-50</sup> and intermittent preventive treatment in pregnant women (IPTp) (n = 4, 33%)<sup>48,51-53</sup> and in infants (IPTi) (n = 3, 25%).<sup>47,50,54</sup> Cost-effectiveness was explored by 2 studies each on SMC<sup>48,49</sup> IPTp,<sup>52,54</sup> and IPTi;<sup>55,56</sup> (see Appendix 7 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

Chemoprevention eligible studies were all published after 2009.

**Seasonal chemoprevention in children (SMC)**

SMC is recommended by the WHO for all children <6 years during each transmission season in areas with highly seasonal malaria transmission in the sub-Sahel region of Africa. A SMC

course was defined as the first dose, given under observation, of each treatment round. All studies had 3 or 4 treatment rounds, with one also evaluating 6 rounds.<sup>49</sup> SMC studies analyzed the delivery costs of using community health workers (CHWs),<sup>46,47,50</sup> volunteers,<sup>48,49</sup> and/or mobile clinics<sup>46,47</sup> or static facilities.<sup>47</sup>

**Intermittent preventive treatment in pregnant women (IPTp)**

IPTp is recommended for all women in their first or second pregnancy as part of antenatal care in malaria-endemic areas in Africa. IPTp studies took place at antenatal clinics<sup>52,54,57</sup> or in the community.<sup>52,53</sup>

**Intermittent preventive treatment of malaria in infants (IPTi)**

IPTi is recommended for infants (<1 year of age) at the time of the second and third rounds of vaccination against DTP and against measles in areas of moderate to high malaria transmission in Africa. IPTi studies examined delivery at public health facilities and/or EPI/mobile clinics.

**Unit cost and cost-effectiveness of chemoprevention**

From a provider perspective, the median economic cost per child receiving a SMC course was \$5.97 (IQR 6.79),<sup>46-50</sup> and from a societal perspective in Ghana it was \$71.<sup>39,48</sup> Training, supervision, and distribution were the largest cost categories (see Appendix 8 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).<sup>46-49</sup> The average cost per IPT dose administered to a pregnant woman was estimated at \$0.86 (95% CI 0.58-1.22), including drug and personnel cost only.<sup>57</sup> The societal cost per

**Table 1.** Summary of cost-effectiveness data from eligible studies, by health outcome measure and intervention type (constant USD 2018).

	ITN	IRS	Larviciding	IPTi	IPTp	SMC	Treatment ±	Surveillance- systems for epidemics	Surveillance- active case detection
<b>Provider economic cost per episode averted</b>									
Median/min-max/ point estimate	\$5.85	-	-	4.38	-	121.50	0.30	1.28-389.82	79.25
Interquartile range (IQR)	5.96	-	-	5.67	-	121.81	1.47	N/A	N/A
Number of point estimates	3	0	0	15	0	10	6	2	1
Number of studies	2 <sup>20,21</sup>	0	0	2 <sup>55,56</sup>	0	2 <sup>48,49</sup>	1 <sup>92</sup>	1 <sup>103</sup>	1 <sup>100</sup>
<b>Societal economic cost per episode averted</b>									
Median/min-max/ point estimate	\$137.34*	-	2.62	-	-	177.34	30.99 <sup>†</sup>	-	-
Interquartile range (IQR)	N/A	-	N/A	-	-	160.28	2.34	-	-
Number of point estimates	1	0	1	0	0	4	6	0	0
Number of studies	1 <sup>19</sup>	0	1 <sup>43</sup>	0	0	2 <sup>48,49</sup>	1 <sup>92</sup>	0	0
<b>Provider economic cost per death averted</b>									
Median/min-max/ point estimate	1281.99	767.60- 913.30	-	271.13	-	3496.26	-	-	39 628.04
Interquartile range (IQR)	998.24	N/A	-	73.84	-	N/A	-	-	N/A
Number of point estimates	16	2	0	4	0	1	0	0	1
Number of studies	5 <sup>14,20,37- 39†</sup>	1 <sup>37</sup>	0	1 <sup>56</sup>	0	1 <sup>48</sup>	0	0	1 <sup>100</sup>
<b>Societal economic cost per death averted</b>									
Median/min-max/ point estimate	7214.30	-	2412.17	-	-	10 449.50	3025.10	-	-
Interquartile range (IQR)	N/A	-	N/A	-	-	N/A	N/A	-	-
Number of point estimates	1	0	1	0	0	1	1	0	0
Number of studies	1 <sup>21,29</sup>	0	1 <sup>43</sup>	0	0	1 <sup>48</sup>	1 <sup>89</sup>	0	0
<b>Provider economic cost per DALY averted</b>									
Median/min-max/ point estimate	44.51	23.22-27.09	-	10.41	-	-	13.5	124.38-623.75	974.46
Interquartile range (IQR)	35.04	N/A	-	13.87	-	-	N/A	N/A	N/A
Number of point estimates	14	2	0	14	0	0	1	2	1
Number of studies	3 <sup>14,20,38,39†</sup>	1 <sup>37</sup>	0	2 <sup>55,56</sup>	0	0	1 <sup>88</sup>	1 <sup>102</sup>	1 <sup>100</sup>
<b>Societal economic cost per DALY averted</b>									
Median/min-max/ point estimate	-	-	46.87	-	1.38- 50.17	-	105.59	-	-
Interquartile range (IQR)	-	-	N/A	-	N/A	-	N/A	-	-
Number of point estimates	0	0	1	0	2	0	1	0	0
Number of studies	0	0	1 <sup>43</sup>	0	2 <sup>52,54</sup>	0	1 <sup>89</sup>	0	0

Summary statistics are presented when there were enough data (refer to number of studies for given category); otherwise point estimate or range are presented. N/A indicates not applicable; -, no data; ±, all data for uncomplicated case treatment; ITN, insecticide-treated net; IRS, indoor residual spraying; IPTi, intermittent preventive treatment for infants; IPTp, intermittent preventive treatment for pregnant women; SMC, seasonal malaria chemoprevention.

\*Study of ITN hammock.

<sup>†</sup>Savings in treatment intervention using ACT compared with monotherapies<sup>91</sup>

<sup>††</sup>Two references cover the same study<sup>37,39</sup>



course of 2 IPTp doses ranged between \$3.02 and \$3.31 depending on the delivery platform, with distribution and user costs reported as main cost categories<sup>52</sup> (see Appendix 7 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>). For IPTi, the median economic cost per infant protected (having received 3 doses) was \$0.53 (IQR 0.59)<sup>51,55,56</sup> with drug cost, training, and IEC as the main unit cost categories (see Appendix 8 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

The cost-effectiveness of SMC was examined in Ghanaian settings only: the median cost per episode averted using different antimalarial drug regimens at community level was \$121.50 (IQR 121.81) from a provider perspective and \$177.34 (IQR 160.28) from a societal perspective.<sup>48,49</sup> The cost per death averted with SMC was \$3496 and \$10 450 from a provider and societal perspective, respectively<sup>48</sup> (Appendix 7 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013> and Table 1). Two studies examined the cost-effectiveness of IPTp, both from the societal perspective,<sup>52,54</sup> with a median cost of \$25.78 per DALY averted (Appendix 7 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013> and Table 1). Finally, depending on the drug regimen used, study location and transmission seasonality, IPTi cost-effectiveness from a provider perspective ranged between \$0.86 and \$22.46 per malaria episode averted,<sup>55,56</sup> \$125.25 and \$376.38 per death averted,<sup>56</sup> and \$3.51 and \$47.95 per DALY averted<sup>55,56</sup> (Appendix 7 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013> and Table 1), largely driven by the very low unit cost of delivering the intervention.

## Diagnosis

All suspected malaria cases should be confirmed with a parasitological test, including RDT or microscopy. Diagnostic eligible studies examined RDT (17, 94%)<sup>58-74</sup> and/or microscopy (n = 8, 50%)<sup>58-62,65,69,70,75</sup> delivered to all-age presumptive malaria cases,<sup>58-68,70,71,73-75</sup> children under 5 years of age with fever,<sup>72</sup> or pregnant women<sup>69</sup> at health facilities,<sup>58-63,65,67-70,72,74,75</sup> drug shops,<sup>64</sup> or in the community<sup>66,71,73</sup> (see Appendix 9 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

### Unit cost of diagnosis

Most studies analyzed the cost per case diagnosed and/or the cost per case diagnosed and treated, while others also examined the cost per additional case diagnosed and treated with RDT or microscopy compared to presumptive diagnosis (n = 9) and/or the cost per additional case diagnosed and/or treated with RDT/microscopy compared to microscopy/RDT (n = 3) (Appendix 9). Four studies estimated RDT unit cost for different malaria transmission risk<sup>59,65,66,68</sup> or prevalence<sup>71</sup> levels. (Appendix 9). From a provider perspective, the median economic cost per case diagnosed with RDT was \$6.06 (IQR 6.23)<sup>59-61,65,69,72</sup> and with microscopy \$2.53 (IQR 5.24)<sup>59-61,65,69</sup>. The main cost categories included personnel, commodities, and supplies (see Appendix 10 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

## Treatment

Five parasite species cause malaria in humans: *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium knowlesi*. The first 2 pose the greatest health threat.<sup>1</sup> A patient with uncomplicated malaria is a patient who presents with symptoms of malaria and a positive parasitological test but with no features of severe malaria. Uncomplicated malaria is assumed to be treated by outpatient health facility

services or at the community level. Severe malaria is generally treated by inpatient healthcare services. Eligible treatment studies related to malaria treatment in children and adults (except pregnant women in their first trimester) with uncomplicated malaria or with severe malaria.

Studies examined the cost of treating *Plasmodium falciparum* malaria (n = 18, 86%)<sup>76-93</sup> or both *Plasmodium falciparum* and *Plasmodium vivax*<sup>94-96</sup> (Appendix 9). Cost-effectiveness was analyzed in 5 studies.<sup>88,89,92,95,96</sup> Most studies were published after 2010<sup>76,78,80-90,94,96</sup> and concerned uncomplicated malaria only,<sup>78,80,82-84,88,89,91-93,95,96</sup> both uncomplicated and severe malaria,<sup>76,79,81,86,90,94</sup> with severe or moderate anemia<sup>81</sup> or severe malaria only<sup>77,85,87</sup> in all ages,<sup>78,80,82,83,89,91,93</sup> infants/children,<sup>76,80,82,83,85,87-90,92,95,96</sup> or pregnant or postpartum women<sup>94</sup> (Appendix 9). Studies examined the cost of treatment at health facilities<sup>76-79,81,84-88,90,92,94-96</sup> or in the community,<sup>79,80,82,83,89,91,93</sup> at times in the context of integrated community case management.<sup>80,82,83</sup> Cost data were commonly reported per uncomplicated and/or severe case treated, occasionally per case diagnosed and treated.<sup>83,92</sup> A few studies also examined the incremental cost or cost-effectiveness of different antimalarial drugs<sup>79,87,88,92,95,96</sup> or delivery platforms<sup>78,89</sup> (Appendix 9).

### Unit cost and cost-effectiveness of treatment

From a provider perspective, the median economic cost was \$9.31 (IQR 8.90) per uncomplicated case treated;<sup>76,78,79,82,84,88,90,94</sup> \$7.15 (IQR 2.77) per uncomplicated case diagnosed and treated<sup>78,83,92</sup> and \$89.93 (IQR 51.10) per severe case treated (Table 1).<sup>76,77,79,88,90,94</sup> From a societal perspective, it was \$11.90 (IQR 11.40) per uncomplicated case diagnosed and treated<sup>83,90,92</sup> and \$145.23 (IQR 118.88) per severe case treated.<sup>77,90</sup> The largest cost categories were personnel and drugs (see Appendix 11 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).

The cost-effectiveness of treating uncomplicated malaria using dihydroartemisinin-piperaquine compared to no treatment was US\$13.50 per DALY averted from a provider perspective in an urban district hospital of Tanzania<sup>88</sup> (Appendix 9). In another district hospital of Tanzania, the median provider cost-effectiveness of artemisinin combination therapy compared to monotherapy was \$0.30 (IQR 1.47) per case averted and resulted in societal savings of \$30.99 (IQR 2.34) per case averted.<sup>92</sup> In rural Ghana, the societal cost-effectiveness of treating under-5 fevers at home using community health workers compared to routine treatment seeking was \$3025 per death averted and \$106 per DALY averted<sup>89</sup> (Appendix 9).

## Surveillance

Surveillance is “the continuous and systemic collection, analysis and interpretation of disease specific data, and the use of that data in the planning, implementation and evaluation of public health practice.”<sup>97</sup> In settings in which transmission is high, surveillance is often integrated into broader routine health information systems; where transmission is low and malaria is being eliminated, surveillance is used to identify, investigate, and eliminate foci of continuing transmission, prevent and cure infections, and confirm elimination. Surveillance studies concerned active case detection (n = 5),<sup>98-102</sup> surveillance systems for malaria epidemics (n = 2),<sup>103,104</sup> and entomological surveillance (n = 2).<sup>105,106</sup> Given the specificity of each surveillance intervention type, unit cost and cost-effectiveness data are presently separately for each intervention.

### Active case detection (ACD)

ACD is used to detect symptomatic cases that are not detected by passive case detection (ie, when a person seeks care) and asymptomatic cases in the community. ACD is generally conducted intermittently outside health facilities by health workers who visit patients at their houses, or elsewhere, and involves administering a parasitological diagnosis of everyone in a targeted population, immediate treatment to positive cases, and follow-up to ensure complete cure.<sup>97</sup> Proactive case detection (pACD) is undertaken in populations that have limited access to facilities or inadequate health-seeking behavior and in high-risk groups. Reactive case detection (rACD) is undertaken in response to an index case (usually seen at a health facility), the epidemiological characteristics of which trigger additional ACD, whereby a household or a population potentially linked to the index case is tested or screened for symptoms and tested before treatment.<sup>97</sup> ACD studies were all published after 2011 and related to rACD<sup>100,102</sup> or pACD.<sup>98,99,101</sup> The provider economic cost of rACD was \$38.63 per person tested and \$32.07 per case treated<sup>100</sup> and for pACD \$4.79 per person tested,<sup>101</sup> \$7.18 per person screened (ie, tested and, if positive, treated),<sup>98</sup> and \$37.87 per case treated.<sup>101</sup> Various types of cost output measures were used, and there was not enough commonality across studies to review unit cost driver data (see Appendix 12 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>). The incremental cost-effectiveness of pACD was \$79.25 per case averted, \$39 628 per death averted, and \$623.75 per DALY averted compared to no pro-ACD.<sup>101</sup> No study examined the cost-effectiveness of rACD.

### Surveillance systems for epidemics

Studies on surveillance systems for epidemics were published before 2010.<sup>103,104</sup> The provider economic cost ranged from \$0.04 per person per year to \$1.47 per person protected and cost-effectiveness between \$1.28 and \$389.82 per case averted depending on transmission intensity (Appendix 12).<sup>104</sup>

### Entomological surveillance

Entomological studies were published after 2011 and concerned the provider cost of community-based mosquito trapping schemes.<sup>105,106</sup> Unit cost measures included the cost per person-night of sampling and the cost per specimen of *Anopheles* caught (Appendix 12). None of the studies provided data on the cost-effectiveness of these interventions using a health outcome measure.

### Combinations of Malaria Control Interventions

Eleven studies examined more than one type of intervention, and all were published on or after 2012, except one (see Appendix 13 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2021.01.013>).<sup>107-117</sup> Studies investigated the cost or cost-effectiveness of combining preventive interventions only,<sup>108,109,111-114,116</sup> commonly vector control<sup>108,113,114,116</sup> in sub-Saharan African settings, while others examined the unit cost of more comprehensive intervention packages in relatively low endemic or elimination settings<sup>107,110,114,115,117</sup> (Fig. 2). These latter studies also analyzed the incremental cost-effectiveness of adding 1 or more interventions to routine activities.<sup>107,117</sup> Given the variable focus of these studies and the different unit cost output and cost-effectiveness outcome measures, no summary statistics could be calculated.

## Discussion

This review identified 103 studies with primary data on the unit cost of delivering the currently WHO-recommended malaria control interventions, either individually or in combination, with approximately one third of the studies also providing evidence on the cost-effectiveness of these interventions. Summarizing the available evidence was a challenge given the high degree of heterogeneity within and across the studied interventions. Overall, cost-effectiveness studies reiterated the value for money of malaria control, although global efforts in methodological and reporting standards are required for the evidence to be useful outside their study contexts.<sup>118-123</sup> These results are important when considering how unit costs and cost-effectiveness data from one study are frequently used in different settings with limited or no adaptation.

The available evidence also concerned largely individual interventions and less so that of comprehensive packages of interventions, which is recommended for effective control.<sup>4</sup> The number of studies of malaria control interventions in combination increased in recent years, although these studies appeared to be more common in lower-transmission settings and designed to assess the incremental cost-effectiveness of adding one intervention on top of another one. These studies shine little light on the change in efficiency of combining the delivery of interventions. The 2 studies that allowed for the comparison of delivering interventions separately or in combination<sup>108</sup> with ITNs and IRS and with ITNs and IPTp<sup>109</sup> suggest the cost savings of combining the delivery of both is minimal. It was difficult to compare the other packages of interventions within the studies themselves, or to the wider cost and cost-effectiveness literature due to the way the data were presented. As health systems move toward more integrated service delivery, it will be important that future cost and health outcome data allow for analyses of efficiency gains and economies of scope. Few studies examined malaria control interventions in the presence of comorbidities. For instance, only 1 study used anemia reduction as an outcome of malaria control despite the close link between the 2 conditions.<sup>124</sup> Studies also rarely explicitly considered the quality of interventions or their equitable coverage when examining unit cost or/and cost-effectiveness.

Our systematic review has some limitations. Non-English search terms and conference abstracts or posters were excluded as well as modeling studies relying exclusively on secondary unit cost or cost-effectiveness data. Study heterogeneity, in terms of analytical perspective, type of cost, unit cost output, and/or cost-effectiveness comparator made it impossible to generate summary statistics for all interventions. Cost-effectiveness results are influenced by the coverage rate of the intervention under investigation, access to other control interventions, and wider health system characteristics. However, these details were rarely reported in the eligible studies. Most studies were conducted within trial contexts as opposed to routine delivery, which may distort unit cost, cost drivers, and cost-effectiveness results. Often, costing studies reported point estimates and not ranges, which likely reflect the real-world uncertainty associated with costing parameters. Such frustrations with costing and cost-effectiveness literature are not unique to malaria control interventions.<sup>119,125</sup> Finally, a quality assessment or risk of bias assessment was originally planned as part of the study. Having reviewed and piloted various

tools,<sup>126-131</sup> it became apparent that they were not suitable, and indeed led to misleading findings. The tools were designed for cost-effectiveness studies with both costs and outcome data primarily from trials as the default. Our review, however, contains both costing and cost-effectiveness studies, and the purely costing studies “scored” consistently lower given they did not cover all the domains. We, therefore, chose not to undertake a quality assessment using a tool that was not fit for the purpose, nor did we think it insightful to develop a bespoke tool for this study given issues of external validity.<sup>131</sup> Deeper reflections on assessing the quality of these data is an important next step.

## Conclusions

To our knowledge, this is the first systematic review to identify and examine the unit cost and cost-effectiveness of all WHO-recommended interventions, implemented individually or in combinations. We identified 103 different costing studies, with nearly one third analyzing the cost-effectiveness of malaria control. The most commonly examined malaria control intervention was ITN, with 26 costing studies and 7 ITN cost-effectiveness analyses, followed by treatment with 21 costing and 5 cost-effectiveness studies. Tanzania, Zambia, and Ghana were by far the most common study settings. The number of studies on combinations of interventions increased recently, although most focused on lower-transmission settings or preventive interventions. Our results indicate that studies used more frequently a provider perspective with more limited societal considerations. Looking to the future, more standardized methods and reporting are needed, as well as guidance on options to transfer data across contexts.

## Supplemental Material

Supplementary data associated with this article can be found in the online version at <https://doi.org/10.1016/j.jval.2021.01.013>.

## Article and Author Information

**Accepted for Publication:** January 4, 2021

**Published Online:** May 18, 2021

doi: <https://doi.org/10.1016/j.jval.2021.01.013>

**Author Affiliations:** Department of Health Policy, London School of Economics and Political Science, London, England, UK (Conteh, Shuford); School of Public Health, Imperial College London, St Mary's Campus, Paddington, England, UK (Conteh); Vector Biology, Liverpool School of Tropical Medicine, Liverpool, England, UK (Agboraw); Department of Infectious Disease Epidemiology, MRC Centre for Global Infectious Disease Analysis, Imperial College London, England, UK (Kont); Department of the Global Malaria Programme, World Health Organization, Geneva, Switzerland (Kolaczinski); Department of Health Systems Governance and Financing, World Health Organization, Geneva, Switzerland (Patouillard).

**Correspondence:** Edith Patouillard, Department of Health Systems Governance and Financing, World Health Organization, Avenue Appia 20, Geneva 1202, Switzerland. Email: [patouillarde@who.int](mailto:patouillarde@who.int)

**Author Contributions:** *Concept and design:* Conteh, Shuford, Kolaczinski, Patouillard

*Acquisition of data:* Conteh, Shuford, Agboraw, Patouillard

*Analysis and interpretation of data:* Conteh, Shuford, Agboraw, Kont, Kolaczinski, Patouillard

*Drafting of the manuscript:* Conteh, Shuford, Kont, Patouillard

*Critical revision of the paper for important intellectual content:* Conteh, Shuford, Agboraw, Kont, Kolaczinski, Patouillard

*Statistical analysis:* Conteh, Patouillard

*Obtaining funding:* Conteh, Kolaczinski, Patouillard

*Administrative, technical, or logistic support:* Shuford, Patouillard

*Supervision:* Conteh, Patouillard

**Conflict of Interest Disclosures:** The authors reported no conflicts of interest.

**Funding/Support:** This work was supported by several grants from the United States Agency for International Development and the Bill and Melinda Gates Foundation.

**Role of the Funder/Sponsor:** The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Acknowledgment:** We thank Jacqueline Cousins, Library Manager and Liaison Librarian at Imperial College London, for her advice on developing the search strategy, Elisa Sicuri at Imperial College London and IS Global Barcelona for extracting data from articles written in the Spanish language, and Camille Pillon at the WHO Global Malaria Programme for her support during the design of Figure 2.

## REFERENCES

1. WHO. *World Malaria Report 2019*. Geneva: World Health Organization; 2019.
2. Feachem RGA, Chen I, Akbari O, et al. Malaria eradication within a generation: ambitious, achievable, and necessary. *Lancet*. 2019;394(10203):1056–1112.
3. RBM Partnership. *Action and Investment to Defeat Malaria 2016-2030*. Geneva: World Health Organization; 2015.
4. WHO. *Global Technical Strategy for malaria 2016-2030*. Geneva: World Health Organization; 2015.
5. WHO. *Malaria Eradication: Benefits, Future Scenarios and Feasibility: Executive Summary*. Geneva: World Health Organization; 2019.
6. Tediosi F, Lengeler C, Castro M, et al. Malaria control (Chapter 13). In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. *Major Infectious Diseases*. 3rd edition. Washington DC: The International Bank for Reconstruction and Development/The World Bank; 2013.
7. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions: a systematic review. *Malar J*. 2011;10:337.
8. White MT, Yeung S, Patouillard E, Cibulskis R. Costs and cost-effectiveness of Plasmodium vivax control. *Am J Trop Med Hyg*. 2016;95(6 Suppl):52–61.
9. Eisele TP, Larsen DA, Walker N, et al. Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001–2010. *Malar J*. 2012;11:93.
10. Wisniewski J, Acosta A, Kolaczinski J, Koenker H, Yukich J. Systematic review and meta-analysis of the cost and cost-effectiveness of distributing insecticide-treated nets for the prevention of malaria. *Acta Trop*. 2020;202:105229.
11. Vassall A, Sweeney S, Kahn J, et al. Reference case for estimating the costs of global health services and interventions. [https://ghcosting.org/pages/standards/reference\\_case](https://ghcosting.org/pages/standards/reference_case). Accessed June , 2018.
12. US Inflation Calculator. <https://www.usinflationcalculator.com>. Accessed January 30, 2019.
13. Historical Currency Converter. <https://www1.oanda.com/fx-for-business/historical-rates/trial>. Accessed January 30, 2019.
14. Becker-Dreps SI, Biddle AK, Pettifor A, et al. Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republic of the Congo. *Am J Trop Med Hyg*. 2009;81(3):496–502.
15. Bonner K, Mwita A, McElroy PD, et al. Design, implementation and evaluation of a national campaign to distribute nine million free LLINs to children under five years of age in Tanzania. *Malar J*. 2011;10(73).
16. De Allegri M. Comparative cost analysis of insecticide-treatment net delivery strategies: sales supported by social marketing and free distribution through antenatal care. *Health Policy Plan*. 2010;25(1):28–38.
17. Grabowsky M, Farrell N, Hawley W, et al. Integrating insecticide-treated bednets into a measles vaccination campaign achieves high, rapid and equitable coverage with direct and voucher-based methods. *Trop Med Int Health*. 2005;10(11):1151–1160.
18. Kolaczinski JH, Kolaczinski K, Kyabayinze D, et al. Costs and effects of two public sector delivery channels for long-lasting insecticidal nets in Uganda. *Malar J*. 2010;9.
19. Morel CM, Thang ND, Erhart A, et al. Cost-effectiveness of long-lasting insecticide-treated hammocks in preventing malaria in south-central Vietnam. *PLOS One*. 2013;8(3):e58205.
20. Mueller DH, Wiseman V, Bakusa D, Morgah K, Dare A, Tchamdjia P. Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. *Malar J*. 2008;7:73.
21. Mulligan JA, Yukich J, Hanson K. Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. *Malar J*. 2008;7(32).



22. Ntuku HM, Ruckstuhl L, Julo-Réminiac J-E, et al. Long-lasting insecticidal net (LLIN) ownership, use and cost of implementation after a mass distribution campaign in Kasai Occidental Province, Democratic Republic of Congo. *Malar J*. 2017;16(1):22.
23. Pemba DF, Bandason E, Namangale J. Comparison of deltamethrin as indoor residual spray or on insecticide treated nets for mosquito control in Lake Chilwa. *Malawi Med J*. 2008;20(3):86–89.
24. Renggli S, Mandike R, Kramer K, et al. Design, implementation and evaluation of a national campaign to deliver 18 million free long-lasting insecticidal nets to uncovered sleeping spaces in Tanzania. *Malar J*. 2013;12(1):85.
25. Scates S JY. *Mass Campaigns and Routine Distribution in Mali*. 2016.
26. Scates S, Yukich J. *School Net Program – Round 3 (SNP3) in Tanzania*. 2017(a).
27. Scates S, Yukich J. *School Net Program – Round 3 (SNP3) in Tanzania*. 2017(b).
28. Sedlmayr R, Fink G, Miller JM, Earle D, Steketee RW. Health impact and cost-effectiveness of a private sector bed net distribution: experimental evidence from Zambia. *Malar J*. 2013;12(1):102.
29. Smith Paintain L, Awini E, Addei S, et al. Evaluation of a universal long-lasting insecticidal net (LLIN) distribution campaign in Ghana: cost effectiveness of distribution and hang-up activities. *Malar J*. 2014;13:71.
30. Stevens W, Wiseman V, Ortiz J, Chavasse D. The costs and effects of a nationwide insecticide-treated net programme: the case of Malawi. *Malar J*. 2005;4(22).
31. WHO. *Costing of ZMCP ITN Program: Report of a Consultation*. Geneva: World Health Organization; 2009.
32. WHO. *Costing of Uganda ITN Activities: Report of a Consultation*. Geneva: World Health Organization; 2009.
33. WHO. *Costing of PSI-Kenya ITN Program: Report of a Consultation*. Geneva: World Health Organization; 2009.
34. Wisniewski J, Yukich J. *Cost Analysis Series Routine Facility-Based Distribution in Main Tanzania. NetWorks/VectorWorks project*. Washington, D.C: USAID and PMI; 2017.
35. Yukich J. *Ghana LLIN Continuous Distribution Cost Analysis. NetWorks/VectorWorks project*. Washington, D.C: USAID; 2014.
36. Yukich J. *Continuous Distribution – Zanzibar. NetWorks/VectorWorks project*. Washington, D.C: USAID; 2016.
37. Yukich J, Tediosi F, Lengeler C. Operations, Costs and Cost-Effectiveness of Five Insecticide-Treated Net Programs (Eritrea, Malawi, Tanzania, Togo, Senegal) and Two Indoor Residual Spraying Programs (Kwa-Zulu-Natal, Mozambique); Washington, D.C: USAID; 2007.
38. Yukich J, Zerom M, Ghebremeskel T, Tediosi F, Lengeler C. Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bed nets. *Malar J*. 2009;8:51.
39. Yukich JO, Lengeler C, Tediosi F, et al. Costs and consequences of large-scale vector control for malaria. *Malar J*. 2008;7(1):258.
40. Cico A, Johns B, Abt Associates I. *PMI IRS Country Programs: 2017 Comparative Cost Analysis*. Rockville, MD. 2018.
41. Dambach P, Schleicher M, Stahl HC, et al. Routine implementation costs of larviciding with *Bacillus thuringiensis israelensis* against malaria vectors in a district in rural Burkina Faso. *Malar J*. 2016;15(1):380.
42. Kusumawathie PHD, Wickremasinghe AR, Karunaweera ND, Wijeyaratne MJS. Costs and effectiveness of application of *Poecilia reticulata* (guppy) and temephos in anopheline mosquito control in river basins below the major dams of Sri Lanka. *Trans R Soc Trop Med Hyg*. 2008;102(7):705–711.
43. Maheu-Giroux M, Castro MC. Cost-effectiveness of larviciding for urban malaria control in Tanzania. *Malar J*. 2014;13:477.
44. Rahman R, Lesser A, Mboera L, Kramer R. Cost of microbial larviciding for malaria control in rural Tanzania. *Trop Med Int Health*. 2016;21(11):1468–1475.
45. Worrall E, Fillingier U. Large-scale use of mosquito larval source management for malaria control in Africa: a cost analysis. *Malar J*. 2011;10.
46. Bojang KA, Akor F, Conteh L, et al. Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial. *PLOS Med*. 2011;8(2):e1000409.
47. Patouillard E, Conteh L, Webster J, Kweku M, Chandramohan D, Greenwood B. Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strategies in Jasikan, Ghana. *PLOS One*. 2011;6(11):e24871.
48. Nonvignon J, Aryeetey GC, Issah S, et al. Cost-effectiveness of seasonal malaria chemoprevention in upper west region of Ghana. *Malar J*. 2016;15:367.
49. Conteh L, Patouillard E, Kweku M, Legood R, Greenwood B, Chandramohan D. Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine and artesunate or sulphadoxine-pyrimethamine in Ghanaian children. *PLOS One*. 2010;5(8):e12223.
50. Pitt C, Ndiaye M, Conteh L, et al. Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis. 2017;32(9):1256–1266.
51. Manzi F, Hutton G, Schellenberg J, et al. From strategy development to routine implementation: the cost of intermittent preventive treatment in infants for malaria control. *BMC Health Serv Res*. 2008;8(165).
52. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. *Trans R Soc Trop Med Hyg*. 2008;102(7):685–693.
53. Orobato N, Austin AM, Abegunde D, et al. Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria. *Malar J*. 2016;15(1):533.
54. Sicuri E, Bardaji A, Nhamposha T, et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in Southern Mozambique. *PLOS One*. 2010;5(10):e13407.
55. Conteh L, Sicuri E, Manzi F, et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. *PLoS One*. 2010;5(6):e10313.
56. Hutton G, Schellenberg D, Tediosi F, et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. *Bull World Health Organ*. 2009;87(2):123–129.
57. Fernandes S, Sicuri E, Halimatou D, et al. Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial. *Malar J*. 2016;15(1):493.
58. Anshah EK, Epokor M, Whitty CJ, Yeung S, Hansen KS. Cost-effectiveness analysis of introducing RDTs for malaria diagnosis as compared to microscopy and presumptive diagnosis in central and peripheral public health facilities in Ghana. *Am J Trop Med Hyg*. 2013;89(4):724–736.
59. Batwala V, Magnussen P, Hansen KS, Nuwaha F. Cost-effectiveness of malaria microscopy and rapid diagnostic tests versus presumptive diagnosis: implications for malaria control in Uganda. *Malar J*. 2011;10:372.
60. Chanda P, Castillo-Riquelme M, Masiye F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. *Cost Eff Resour Alloc*. 2009;7(5).
61. de Oliveira MR, de Castro Gomes A, Toscano CM. Cost effectiveness of OptiMal rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil. *Malar J*. 2010;9:277.
62. de Oliveira MR, Giozza SP, Peixoto HM, Romero GA. Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil. *Malar J*. 2012;11:390.
63. Faye A, Ndiaye P, Diagne-Camara M, et al. [Economic evaluation of rapid diagnostic tests in malaria treatment]. [French]. *Sante publique*. 2010;22(6):617–623.
64. Hansen KS, Clarke SE, Lal S, Magnussen P, Mbonye AK. Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda. 2017;12(12):e0189758.
65. Hansen KS, Grieve E, Mikhail A, et al. Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan. *Malar J*. 2015;14:217.
66. Hansen KS, Ndyomugenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. 2017;15:15.
67. Lemma H, San Sebastian M, Lofgren C, Barnabas G. Cost-effectiveness of three malaria treatment strategies in rural Tigray, Ethiopia where both *Plasmodium falciparum* and *Plasmodium vivax* co-dominate. *Cost Eff Resour Alloc*. 2011;9:2.
68. Lubell Y, Keyburn H, Mbakilwa H, et al. The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. *Am J Trop Med Hyg*. 2007;77(6 Suppl):128–132.
69. Matangila JR, Lufuluabo J, Ibalanki AL, Inocencio Da Luz RA, Lutumba P, Van Geertruyden JP. Asymptomatic *Plasmodium falciparum* infection is associated with anaemia in pregnancy and can be more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, Democratic Republic of the Congo. *Malar J*. 2014;13(1):132.
70. Ogunniyi A, Dairo MD, Dada-Adegbola H, et al. Cost-effectiveness and validity assessment of cyscope microscope, quantitative buffy coat microscope, and rapid diagnostic kit for malaria diagnosis among clinic attendees in Ibadan, Nigeria. *Malar Res Treat*. 2016;2016:5242498.
71. Rolland E, Checchi F, Pinoges L, Balkan S, Guthmann JP, Guerin PJ. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective? *Trop Med Int Health*. 2006;11(4):398–408.
72. Tawiah T, Hansen KS, Baiden F, et al. Cost-effectiveness analysis of test-based versus presumptive treatment of uncomplicated malaria in children under five years in an area of high transmission in central Ghana. *PLOS One*. 2016;11(10).
73. Willcox ML, Sanogo F, Graz B, et al. Rapid diagnostic tests for the home-based management of malaria, in a high-transmission area. *Ann Trop Med PH*. 2009;103(1):3–16.
74. Yukich J, D'Acromont V, Kahama J, Swai N, Lengeler C. Cost savings with rapid diagnostic tests for malaria in low-transmission areas: evidence from Dar es Salaam, Tanzania. *Am J Trop Med Hyg*. 2010;83(1):61–68.
75. Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH. Cost comparison of microscopy vs. empiric treatment for malaria in southwestern Nigeria: A prospective study. *Malar J*. 2010;9(1):371.
76. Abotsi AK. *Cost burden of infant malaria treatment on households and health institutions in the upper east region*. University of Cape Coast Journal of Arts and Social Sciences; 2012.
77. Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. *Cost Eff Resour Alloc*. 2009;7(3).
78. Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. *Malar J*. 2011;10:159.

79. Chanda P, Masiye F, Chitah BM, et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. *Malar J.* 2007;6(21).
80. Collins D, Jarrah Z, Gilmartin C, Saya U. The costs of integrated community case management (iCCM) programs: a multi-country analysis. *J Glob Health.* 2014;4(2):020407.
81. Comfort AB, van Dijk JH, Mharakurwa S, et al. Hospitalizations and costs incurred at the facility level after scale-up of malaria control: pre-post comparisons from two hospitals in Zambia. *Am J Trop Med Hyg.* 2014;90(1):20–32.
82. Daviaud E, Besada D, Leon N, et al. Costs of implementing integrated community case management (iCCM) in six African countries: implications for sustainability. *J Glob Health.* 2017;7(1):010403.
83. Escribano Ferrer B, Hansen KS, Gyaopong M, et al. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia. *Malar J.* 2017;16(1):277.
84. Ezenduka CC, Falleiros DR, Godman BB. Evaluating the treatment costs for uncomplicated malaria at a public healthcare facility in Nigeria and the implications. *Pharmacoeconomics.* 2017;1(3):185–194.
85. Ferrari G, Maggi Ntuku H, Burri C, et al. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study. *Trop Med Int Health.* 2015;1:91.
86. Kyaw SS, Drake T, Ruangveerayuth R, Chierakul W, White NJ, Newton PN. Cost of treating inpatient falciparum malaria on the Thai-Myanmar border. *Malar J.* 2014;13:416.
87. Maka DE, Chiabi A, Obadeyi B, et al. Economic evaluation of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital-Cameroon: a cost analysis. *Malar J.* 2016;15(1):587.
88. Mori AT, Ngalesoni F, Norheim OF, Robberstad B. Cost-effectiveness of dihydroartemisinin-piperazine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. *Malar J.* 2014;13(1):363.
89. Nonvignon J, Chinbuah MA, Gyaopong M, et al. Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District. *Trop Med Int Health.* 2012;17(8):951–957.
90. Onwujekwe O, Uguru N, Etiaba E, Chikezie I, Uzochukwu B, Adjagba A. The economic burden of malaria on households and the health system in Enugu state southeast Nigeria. *PLOS One.* 2013;8(11):e78362.
91. Onwujekwe O, Uzochukwu B, Ojukwu J, Dike N, Shu E. Feasibility of a community health worker strategy for providing near and appropriate treatment of malaria in southeast Nigeria: an analysis of activities, costs and outcomes. *Acta Trop.* 2007;101(2):95–105.
92. Wiseman V, Kim M, Mutabingwa TK, Whitty CJM. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. *PLOS Med.* 2006;3(10):1844–1850.
93. Yeung S, Van Damme W, Socheat D, White NJ, Mills A. Cost of increasing access to artemisinin combination therapy: the Cambodian experience. *Malar J.* 2008;7(84).
94. Botto-Menezes C, Bardaji A, Dos Santos Campos G, et al. Costs associated with malaria in pregnancy in the Brazilian Amazon, a low endemic area where plasmodium vivax predominates. *PLOS Negl Trop Dis.* 2016;10(3):e0004494.
95. Davis WA, Clarke PM, Siba PM, et al. Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. *Bull World Health Organ.* 2011;89(3):211–220.
96. Moore BR, Davis WA, Clarke PM, Robinson LJ, Laman M, Davis TME. Cost-effectiveness of artemisinin-naphthoquinone versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children. *Malar J.* 2017;16(1):438.
97. WHO. *Malaria Surveillance, Monitoring and Evaluation: a reference manual.* Geneva: World Health Organization; 2018.
98. Drake TL, Okello G, Njagi K, et al. Cost analysis of school-based intermittent screening and treatment of malaria in Kenya. *Malar J.* 2011;10:273.
99. Hamaizna B, Moonga H, Sikaala CH, et al. Monitoring, characterization and control of chronic, symptomatic malaria infections in rural Zambia through monthly household visits by paid community health workers. *Malar J.* 2014;13:128.
100. Larson BA, Ngoma T, Silumbe K, et al. A framework for evaluating the costs of malaria elimination interventions: an application to reactive case detection in Southern Province of Zambia, 2014. *Malar J.* 2016;15.
101. Silumbe K, Yukich JO, Hamaizna B, et al. Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia. *Malar J.* 2015;14:211.
102. Zelman BW, Baral R, Zarlinda I, et al. Costs and cost-effectiveness of malaria reactive case detection using loop-mediated isothermal amplification compared to microscopy in the low transmission setting of Aceh Province, Indonesia. *Malar J.* 2018;17.
103. Mueller DH, Abeku TA, Okia M, Rapuoda B, Cox J. Costs of early detection systems for epidemic malaria in highland areas of Kenya and Uganda. *Malar J.* 2009;8:17.
104. Worrall E, Connor SJ, Thomson MC. Improving the cost-effectiveness of IRS with climate informed health surveillance systems. *Malar J.* 2008;7:263.
105. Chaki PP, Mlacha Y, Msellemu D, et al. An affordable, quality-assured community-based system for high-resolution entomological surveillance of vector mosquitoes that reflects human malaria infection risk patterns. *Malar J.* 2012;11:172.
106. Sikaala CH, Chinula D, Chanda J, et al. A cost-effective, community-based, mosquito-trapping scheme that captures spatial and temporal heterogeneities of malaria transmission in rural Zambia. *Malar J.* 2014;13(1):225.
107. Giron SL, Mateus JC, Castellar CE. Cost-effectiveness analysis of two strategies for malaria control in the urban area of Buenaventura, Colombia. [Spanish]. *Biomedica.* 2006;26(3):379–386.
108. Hailu A, Lindtjorn B, Deressa W, Gari T, Loha E, Robberstad B. Cost-effectiveness of a combined intervention of long lasting insecticidal nets and indoor residual spraying compared with each intervention alone for malaria prevention in Ethiopia. *Cost Eff Resour Alloc.* 2018;16(1):61.
109. Hansen KS, Ndyomugenyi R, Magnussen P, Clarke SE. Cost-effectiveness analysis of three health interventions to prevent malaria in pregnancy in an area of low transmission in Uganda. *Int Health.* 2012;4(1):38–46.
110. Haque U, Overgaard HJ, Clements ACA, et al. Malaria burden and control in Bangladesh and prospects for elimination: an epidemiological and economic assessment. *Lancet Glob Health.* 2014;2(2):e98–e105.
111. Howard N, Guinness L, Rowland M, Durrani N, Hansen KS. Cost-effectiveness of adding indoor residual spraying to case management in Afghan refugee settlements in Northwest Pakistan during a prolonged malaria epidemic. *PLOS Negl Trop Dis.* 2017;11(10):e0005935.
112. Maccario R, Rouhani S, Drake T, et al. Cost analysis of a school-based comprehensive malaria program in primary schools in Sikasso region, Mali. *BMC Public Health.* 2017;17(1):572.
113. Makoutode CP, Audibert M, Massougbdji A. Analysis of the cost-effectiveness of the implementation of indoor residual spraying and distribution of long-lasting insecticidal nets in the municipality of Kouande and municipality of Copargo in Benin. *Cost Eff. Resour Alloc.* 2014;12.
114. Rezaei-Hemami M, Akbari-Sari A, Raiesi A, Vatandoost H, Majdzadeh R. Cost effectiveness of malaria interventions from preelimination through elimination: a study in Iran. *J Arthropod Borne Dis.* 2014;8(1):43–52.
115. Smith Gueye C, Gerigk M, Newby G, Lourenco C, Uusiku P, Liu J. Namibia's path toward malaria elimination: a case study of malaria strategies and costs along the northern border. *BMC Public Health.* 2014;14:1190.
116. Stelmach R, Colaco R, Llaji S, McFarland D, Reithinger R. Cost-effectiveness of indoor residual spraying of households with insecticide for malaria prevention and control in Tanzania. *Am J Trop Med Hyg.* 2018;16:16.
117. Sun DW, Du JW, Wang GZ, et al. A cost-effectiveness analysis of plasmodium falciparum malaria elimination in Hainan Province, 2002–2012. *Am J Trop Med Hyg.* 2015;93(6):1240–1248.
118. Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. *Bull World Health Organ.* 2016;94(12):925–930.
119. Cameron DB, Mustafa Diab M, Carroll LN, et al. The state of costing research for HIV interventions in sub-Saharan Africa. *Afr J AIDS Res.* 2019;18(4):277–288.
120. Edoke IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. *Health Policy Plan.* 2020;35(5):546–555.
121. Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies. *Value Health.* 2018;21(7):759–761.
122. Rehfuss EA, Stratil JM, Scheel IB, Portela A, Norris SL, Baltussen R. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. *BMJ Glob Health.* 2019;4(Suppl 1):e000844.
123. Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. *Pharmacoeconomics.* 2018;36(5):509–522.
124. WHO. *World Malaria Report 2018.* Geneva: World Health Organization; 2018.
125. DeCormier Plosky W, Bollinger LA, Alexander L, et al. Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB: methodology and lessons learned. *Afr J AIDS Res.* 2019;18(4):263–276.
126. Boutron I, Page M, Higgins J, Altman D, Lundh A, A H. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, et al., eds. *Cochrane Handbook for Systematic Reviews of Interventions version 6.1. (updated September 2020).* Cochrane; 2020.
127. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. *Int J Technol Assess Health Care.* 2005;21(2):240–245.
128. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. *J Manag Care Pharm.* 2003;9(1):53–61.
129. Drucker AM, Fleming P, Chan A-W. Research techniques made simple: assessing risk of bias in systematic reviews. *J Invest Dermatol.* 2016;136(11):e109–e114.
130. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. *Value Health.* 2013;16(2):231–250.
131. Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. *Value Health.* 2019;22(3):377–382.